Changing the trajectory of health for humanity requires we put people first. When healthy people and families thrive in healthier communities, everything else will follow. At Johnson & Johnson, we believe in the importance of investing in people on the front lines of care for the world's most vulnerable people, their families and their communities. By galvanizing partners, connecting communities, and leveraging our employees and extensive local reach, we help activate the resources—and resolve—needed to address the world’s most pressing health challenges.
Johnson & Johnson has a global, regional and local business presence through more than 230 operating companies in 60 countries. The Company’s direct business activities have a multiplying effect that ripples through local economies. The Company implements and evaluates programs that drive social impact in areas influencing the health of communities, including strengthening health systems and improving individual health behaviors and outcomes.
Responsibility for community impact and development is held by numerous enterprise, regional, and local Johnson & Johnson teams, particularly: Worldwide Government Affairs & Policy (GA&P) and Global Community Impact, as well as Global Public Health, addressed elsewhere in this report.
Worldwide Government Affairs & Policy
Johnson & Johnson GA&P, with worldwide leadership, regional leaders, and country-level colleagues, is responsible for advocating for public policies that expand access to high-quality, affordable health care worldwide and promoting the value of innovation to improve the standard of patient care and support sustainable business growth. Within GA&P, the Global Health Policy organization focuses on health care market dynamics and establishing the Johnson & Johnson perspective on relevant political and government activity. The Regulatory, Compliance & Government Affairs Committee of the Johnson & Johnson Board of Directors provides oversight of GA&P.
In the last several years, Worldwide Government Affairs and Global Health Policy have commissioned and led more than a dozen econometric studies estimating the economic and social impacts of Johnson & Johnson in select markets to equip the Company for smarter engagement on local health and health policy issues. Among the studies completed, the five countries with the largest economic impact are the United States, Belgium, France, the United Kingdom and Germany. Economic impact is determined by considering factors such as economic activity associated with our business segments, generation of taxes, the value that Johnson & Johnson adds to its products through in-country activities, and the Company's indirect impact on other sectors of the economy. The studies have also included three of the traditional BRIC emerging markets, Brazil, Russia, and China. Additional econometric studies are in progress, including in India.
The Johnson & Johnson economic footprint reports have been used to support engagements with governments and other stakeholders on key economic and health policy issues by the Company’s senior management as well as GA&P representatives. Particularly, the footprint reports, encapsulating the Company’s physical and manufacturing investments and local job creation, have helped address localization pressures from governments in BRIC markets requiring multinational corporations to make more local investments. GRI 203-2
Our Health for Humanity 2020 Goals include a goal to drive policy thought leadership and strategic engagements to expand health care access and coverage in three emerging markets (Brazil, China and India), and lead three-to-five pilot programs to demonstrate the results of these efforts.
Global Community Impact
Our Global Community Impact (GCI) focus is to support and champion the people on the front lines who are at the heart of delivering care. Every individual we support builds a stronger community. And every community we support builds towards a global state of enhanced human health and well-being. Our work is driven by regional needs, and focuses on having lasting effects on communities around the world.
Our Guiding Principles
Our GCI work is managed within guidelines approved by the Johnson & Johnson Executive Committee. The strategic philanthropy budget is established before the start of each fiscal year, so our giving as a percentage of year-end pretax income varies from year to year, with fluctuations in year-end pretax income. See this yearly figure reported in our Data Summary.
In 2016, we marked a decade of Johnson & Johnson partnership with mothers2mothers. Work over the past 10 years has reached 1.3 million HIV-positive women in nine countries. Only 2.1 percent of women in their programs transmitted HIV to their children—a programmatic success that the Joint United Nations Programme on HIV/AIDS (UNAIDS) equates to virtual elimination of pediatric HIV.
At AIDS 2016, Johnson & Johnson alongside the Elizabeth Glaser Pediatric AIDS Foundation, UNAIDS and the U.S. President's Emergency Plan for AIDS Relief program launched the “Start Free, Stay Free, AIDS Free” campaign to carry on the work of the Global Plan, drive implementers and funders, and host governments to end mother-to-child transmission of HIV by 2020.
We launched two new public-private partnerships in 2016 to improve maternal and newborn care. Born On Time prioritizes the prevention of pre-term birth, now the leading cause of death globally in children under five, with a focus on programs in Bangladesh, Ethiopia and Mali. In Haiti and Liberia, two of the most difficult places in the world to give birth, we are partnering with the United Nations Population Fund on Safe Birth Even Here to promote safe birth outcomes with the goal of reducing both maternal and infant mortality.
We rolled out WiSTEM2D in the United States, Africa and Europe to help girls between the ages of 5 and 18 to stay on the STEM track. With Johnson & Johnson employees serving as mentors, our goal is to reach 1 million girls by 2020 through after-school programs.
With support from Johnson & Johnson, Women Deliver provided seed grants to Young Leaders to plan and implement advocacy projects to improve health in their local communities. As a founding partner of the Young Leaders Program, we have increased the advocacy capacity, leadership and engagement of hundreds of young leaders to champion reproductive, maternal, newborn, child, and adolescent health.
In 2016, the Johnson & Johnson Corporate Citizenship Trust celebrated 15 years of partnership with the Aga Khan Development Network (AKDN), helping communities in the developing world improve local capacities in three critical areas: Nursing and Midwifery, Early Childhood Development, and Community Health Care. The AKDN has been a secondment partner of the Trust since 2014, and many Johnson & Johnson employees in our Europe, Middle East and Africa region have taken part in AKDN-related secondment programs.
More than 20,000 of our employees engaged in volunteering in key programs, including one example with our Johnson & Johnson Diabetes Care programs. We saw our employees throughout the world devote more than 15,000 hours in support of initiatives.
We are among the largest corporate donors, having contributed $1.2 billion in cash and products toward nearly 500 programs in more than 60 countries, impacting tens of millions of lives worldwide. The Company contributed $188 million in cash to organizations in the United States and around the world for corporate and operating companies’ programs and projects. This included more than $13 million allocated through our U.S. Matching Gifts program; Johnson & Johnson double-matched employee contributions in 2016 and made one-for-one contributions for donations from retirees, up to $10,000, for qualified nonprofit U.S. 501(c)(3) organizations. GRI 203-1
Johnson & Johnson companies made $1 billion in non-cash contributions (product donations are reported at fair market value, which is consistent with the reporting methods of nonprofit organizations). Of these contributions, the Company donated medicines valued at approximately $697 million to support 2016 operations of the Johnson & Johnson Patient Assistance Foundation, enabling the Foundation to provide medicines at no cost to more than 75,000 patients in the United States. The balance of non-cash contributions went to private voluntary organizations that assist medically underserved people in developing countries and provide emergency disaster relief.
In 2016 the United Nations set a new global agenda for human progress and social impact through 17 Sustainable Development Goals (SDGs) of the 2030 Agenda for Sustainable Development. Johnson & Johnson is committing to do our part.
We are dedicating our expertise, ideas, and ingenuity to catalyze efforts to achieve SDG 3: Good Health and Well-being—Ensure healthy lives and promote well-being for all at all ages—which is at the heart of the SDGs and the core of our business.
We focus on the importance of Goal 5: Gender Equality—Achieve gender equality and empowering all women and girls—as critical to improving the health and well-being of individuals and communities around the world.
Our efforts, collaborating with both global and community-based partners to address the world’s most pressing health challenges, are founded in the principles of Goal 17: Partnerships for the Goals—Strengthen the means of implementation and revitalize the global partnership for sustainable development.
Good health plays a fundamental part in all 17 of the SDGs. That is why Johnson & Johnson is taking a holistic, people-centered approach to develop cross-cutting solutions across five inter-connected focus areas in which we are uniquely positioned to create sustainable and scalable impact: Health Workforce, Women’s & Children’s Health, Essential Surgery, Environmental Health, and Global Disease Challenges.
Our commitment, further broken down into bold, five-year targets within these five areas, aims to mobilize and inspire our employees, our customers, our communities, and our global network to solve some of the world’s greatest health challenges.